Daniel G. Anderson

Daniel G. Anderson is a Professor in the Department of Chemical Engineering and the Institute for Medical Engineering and Science at the Massachusetts Institute of Technology. He holds additional appointments as a Member of the Marble Center for Cancer Nanomedicine, Associate Member of the Broad Institute of MIT and Harvard, and Associate Member of the Ragon Institute at MGH, MIT and Harvard. His research spans multiple institutions including the Koch Institute for Integrative Cancer Research and the Harvard-MIT Division of Health Science and Technology.

Anderson received his BA in mathematics and biology from the University of California at Santa Cruz and his PhD in molecular genetics from the University of California at Davis. His educational background laid the foundation for his interdisciplinary approach to biomedical engineering and nanotechnology.

Professor Anderson's research focuses on the intersection of biology and engineering to develop novel medical devices and therapies. His laboratory pioneers the development of smart materials, nanoparticles for drug delivery, living medical devices, and next-generation nanotherapeutics. Key research areas include creating synthetic nanoparticles that act as artificial viruses for genetic therapy delivery, developing biomaterials for tissue engineering, and engineering responsive drug delivery systems that can integrate with the body for customized treatment. His work spans applications in cancer, diabetes, and other chronic diseases.

Analysis of Anderson's recent publications reveals a strong trend toward RNA therapeutics, particularly in the development of lipid nanoparticles for mRNA delivery. His research increasingly incorporates AI-guided design approaches and focuses on targeted delivery to specific organs like the lungs. There's also a clear progression toward clinical applications, with several technologies moving from basic research to clinical development.

• 2023 Wilhelm Exner Medal for contributions to nanotherapeutics and biomaterials
• Elected to the National Academy of Inventors for inventions with tangible societal impact
• Elected to the National Academy of Medicine for outstanding contributions to medical research

Professor Anderson has advised numerous graduate students, postdocs, and researchers, many of whom have received funding through the Gordon Tang Goodwin Student Support Fund to attend major scientific conferences. His lab has secured significant funding, including a $25 million grant from Sanofi to develop next-generation delivery technology for mRNA vaccines and therapeutics. Anderson's research has resulted in over 500 publications, patents, and patent applications, and has led to the founding of multiple biotechnology companies including Living Proof, Olivo Labs, CRISPR Therapeutics, Sigilon Therapeutics, Verseau Therapeutics, Orna Therapeutics, and VasoRx. His laboratory continues to push the boundaries of what's possible in medical device engineering and therapeutic delivery.